Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

FDA Approves Nivolumab/Ipilimumab for Frontline RCC

April 16th 2018

The FDA has approved the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma.

Dr. Choueiri Highlights the Latest in Genitourinary Cancer Research

April 12th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the latest treatments in genitourinary (GU) cancers.

Adjuvant Axitinib Falls Short in Phase III RCC Trial

April 11th 2018

Adjuvant axitinib did not extend disease-free survival versus placebo for patients at high risk of recurrent renal cell carcinoma after nephrectomy, according to findings from the phase III ATLAS trial.

POUT Data Show Benefit of Adjuvant Chemotherapy in Patients With UTUC

April 11th 2018

Data from the phase III POUT clinical trial demonstrated that adjuvant platinum-based chemotherapy improves disease-free survival and metastasis-free survival in patients with upper tract urothelial carcinoma.

Surgical Challenges Remain Among Recent Successes in Kidney Cancer

April 10th 2018

Hyung L. Kim, MD, discusses perioperative systemic therapy for patients with kidney cancer.

Standardization, Simplification Needed for Wider Adoption of Robotic Cystectomy

April 10th 2018

Amit Gupta, MD, discusses the superiority of robotic cystectomy compared with open cystectomies and its relevance in the current treatment landscape of bladder cancer.

Dr. Harshman on the PROTECT Trial in Patients With Locally Advanced RCC

April 6th 2018

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses how the PROTECT trial sought to answer the controversial results of the ASSURE and S-TRAC trials.

Dr. Nanus Discusses Immunotherapy in Kidney Cancer

April 6th 2018

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of immunotherapy in the treatment of patients with kidney cancer.

Dr. Bellmunt on The Cancer Genome Atlas Project in Bladder Cancer

April 5th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses The Cancer Genome Atlas (TCGA) project in bladder cancer.

Dr. Wei on the Use of Cabozantinib in Advanced Kidney Cancer

April 5th 2018

Xiao X. Wei, MD, MAS, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the side effect profile of cabozantinib (Cabometyx) in advanced kidney cancer.

Dr. Sonpavde on Immunotherapy Plus Chemotherapy in Bladder Cancer

April 4th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses immunotherapy plus chemotherapy in bladder cancer.

Dr. Balar Discusses the Impact of Immunotherapy on Bladder Cancer

April 2nd 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the impact of immunotherapy on patients with bladder cancer.

Dr. Bellmunt on Immunotherapy Combination Trials in Bladder Cancer

March 28th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses trials investigating combinations with immunotherapy for patients with bladder cancer.

Dr. Nanus Discusses Adjuvant Therapy for RCC

March 27th 2018

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses adjuvant therapy for patients with renal cell carcinoma.

European Panel Backs New Nivolumab Dosing Schedules

March 26th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended adding the option of a 4-week dosing schedule to the label for nivolumab for the treatment of patients with advanced melanoma and previously treated renal cell carcinoma (RCC).

FDA Grants Enfortumab Vedotin Breakthrough Designation for Urothelial Carcinoma

March 26th 2018

The FDA has granted enfortumab vedotin a breakthrough therapy designation for patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint therapy.

Gomella Gives Predictions for Prostate Cancer Advances in 2018

March 25th 2018

Leonard G. Gomella, MD, shares his insight on this year's expected advances in the field of prostate cancer.

Dr. Hussain on the Importance of Next-Generation Sequencing in Prostate Cancer

March 24th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Progessor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cncer Center, Northwestern University Feinberg School of Medicine, discusses the importance of next-generation sequencing in prostate cancer.

Dr. Sznol Discusses Advancements in Immunotherapy for RCC

March 24th 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses advancements in immunotherapy for the treatment of patients with renal cell carcinoma.

Dr. Nanus on Managing Side Effects from Immunotherapy in RCC

March 23rd 2018

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses managing side effects from immunotherapy in renal cell carcinoma (RCC).